

Emcure

Ref: EPL/CS/SE/0021/2026

Date: March 09, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of Mr. C. S. Muralidharan as an Additional Director (Non-Executive and Independent) and as an Independent Director of the Company

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') read with Schedule III of aforesaid regulation and HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 and based on the recommendation of the Nomination and Remuneration Committee, we hereby inform that the Board of Directors of the Company at its meeting held today i.e. Monday, March 09, 2026, has approved the appointment of Mr. C S Muralidharan (DIN: 00014740) as an Additional Director (Non-Executive and Independent) with effect from April 01, 2026, and as an Independent Director for first term of three (3) consecutive years, with effect from April 01, 2026, subject to approval of Members of the Company.

Mr. C S Muralidharan is not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India ('SEBI') order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and he is not related to any Director(s) or Key Managerial Personnel(s) of the Company.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are enclosed herewith.

The meeting of the Board of Directors of the Company commenced at 12:15 p.m. (IST) and concluded at 12:40 p.m. (IST).

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 - 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

Emcure

You are requested to kindly take the above on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Amruta Yangalwar
Company Secretary & Compliance Officer
Membership Number: A25687

Encl: As above

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Emcure

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	Particulars	Information
1	Name of the Director	Mr. C S Muralidharan
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment as an Additional Director (Non-Executive and Independent) with effect from April 01, 2026 and as an Independent Director of the Company with effect from April 01, 2026.
3	Date of appointment/ re-appointment/ cessation (as applicable) & term of appointment/ re-appointment	Appointment as an Additional Director (Non-Executive and Independent) with effect from April 01, 2026 and as an Independent Director for first term of three (3) consecutive years, with effect from April 01, 2026, subject to approval of Members of the Company.
4	Brief profile (in case of appointment);	<p>Mr. C. S. Muralidharan has overall 40 years of corporate experience spread across hydro-carbon and pharmaceutical sectors. He has held various board and senior leadership positions across multiple entities in India, Asia and Europe. He has had proactive engagements with the Board demonstrating strong partnership on Strategy M&A transactions, enterprise risk management, capital restructuring, enterprise transformation and ESG initiatives. He has previously worked with organizations like Indian Oil Corporation Limited, Ranbaxy Group, Lupin Limited, Matrix Laboratories Limited, Watson Group and in his last role, was associated with Sun Pharmaceutical Industries Limited, as Group Chief Financial Officer, where he was responsible for global finance, strategy, M&A, investor relations, governance and compliance.</p> <p>Mr. Muralidharan is a Cost & Management Accountant with a Master's degree in Commerce and has completed the Executive Program in General Management from Booth School of Business, University of Chicago.</p>
5	Disclosure of relationships between Directors (in case of appointment of a director).	Mr. Muralidharan is not related to any Director of the Company.

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251